I’m excited to announce that ACS is partnering with National Cancer Institute and Cancer Research UK for the 1st annual Cancer Prevention Research Conference in Boston this June! The deadline for early bird registration and abstract applications is 4/12. For more info, visit: app.groupize.com/organizations/…

Listening to patient preferences is important to developing real-world new multiple myeloma treatments. iPREFER study: clinicaltrials.gov/study/NCT06322… The Christie NHS

Fabulous SAB reviewing latest clinical data and plans going forward. There remains a clear need for novel, well tolerated oral agents in RR multiple myeloma.

There is a continuing squeeze on hospitals and on oncology workforce capacity. There is a role for novel effective oral drugs taken at home, in the community.

Inobrodib, our pioneering p300/CBP inhibitor oral drug, can address a clear need in multiple myeloma therapy, post antibody-based drugs.

Why a British purple tomato is causing a scandal thetimes.co.uk/article/44532c…

Can biotech startups upstage big pharma? Percentage of clinical trials run by small biopharma over 70% of total. $XBI economist.com/business/2024/…

More turnover than usual at pharmas these days, with lots of great people exploring new opportunities in the biotech ecosystem. Immigrants from pharma can learn more at gateway.racap.com, a website we created to build and level up boards but is useful for all executives.

Healthcare systems face a double issue: declining numbers of oncology experts and a lack of hospital space. See post: linkedin.com/feed/update/ur…

Congratulations to our Director Rebecca Fitzgerald Rebecca Fitzgerald Lab who has been elected to the Fellowship of the Royal Society this year. Hugely deserved recognition of great scientific achievement. Early Cancer Institute, University of Cambridge

Breaking News 👉 #ASCO24 ASCO Abstracts are out! For full length abstracts, here is the weblink👉tinyurl.com/4mj8nb73 OncoAlert UroToday.com Uromigos Oncology Brothers

Sir David McMurtry to leave Renishaw thetimes.com/article/b5564c…

France v Spain England v Netherlands? Next week might feel like 1652

Let’s make Britain the life sciences powerhouse it deserves to be thetimes.com/article/d4a417…

Delighted to confirm $35m from RA Capital Mgmt, plus support from the American Cancer Society’s BrightEdge. cellcentric.com/press-release/… Endpoints: endpts.com/ra-capital-inv…

Fabulous to see inobrodib, our pioneering oral p300/CBP inhibitor drug, maintain full momentum towards registration studies. See: cellcentric.com/press-release/…

Great to have Laura Stoppel, RA Capital, join the CellCentric board, alongside Irena Melnikova of Pfizer Ventures. Exciting times as we press on with developing inobrodib!

Beyond and alongside antibody-based therapies for multiple myeloma, there is a need for novel oral agents, that can be taken in the community.

We're pleased to share that Dr Stella Peace has been appointed Interim Executive Chair of @InnovateUK from Oct 2024. Currently Innovate UK’s executive director for healthy living & agriculture, she has a strong background in international technology. 🔗 orlo.uk/cvcVw

⁦Watching from a distance ⁦Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰⁩ at his best at #SOHO24 #mmsm